Dunkle LM, et al. - Authors performed comparison of new quadrivalent recombinant influenza vaccine (RIV4) with a standard-dose egg-grown, quadrivalent inactivated influenza vaccine (IIV4) for immunogenicity and safety in adults 18–49 years of age. Findings suggested that the two vaccines had comparable immunogenicity, safety and tolerability.